Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
Letrozole Basic information |
Pharmacological Function Distinctions Between Letrozole and Anastrozole Adverse Reactions and Side Effects Chemical Properties Usage Production Method |
Product Name: | Letrozole |
Synonyms: | 4,4'-(1H-1,2,4-TRIAZOL-1-YLMETHYLENE) BIS-BENZONITRILE;FEMARA;CGS-20267;LETROZOL;LETROZOLE;LetrozoleUsp28;Letrozole99%;CGS-20267, Femara |
CAS: | 112809-51-5 |
MF: | C17H11N5 |
MW: | 285.3 |
EINECS: | |
Product Categories: | Anti-Cancer;Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Letrozole;Antineoplastic;All Inhibitors;anti-neoplastic;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API's;APIs;Antibiotics;Aromatics;Heterocycles;ELOXATIN;Anti-cancer&immunity |
Mol File: | 112809-51-5.mol |
Letrozole Chemical Properties |
mp | 181-183°C |
storage temp. | -20°C Freezer |
CAS DataBase Reference | 112809-51-5(CAS DataBase Reference) |
Safety Information |
Hazard Codes | Xi |
Risk Statements | 36/37/38 |
Safety Statements | 26-36 |
Hazardous Substances Data | 112809-51-5(Hazardous Substances Data) |
MSDS Information |
Provider | Language |
---|---|
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile | English |
Letrozole Usage And Synthesis |
Pharmacological Function |
Letrozole is a new generation of selective aromatase inhibitors. It is a synthetic benzyl triazole derivative, can inhibit aromatase and decrease estrogen levels, further eliminates the stimulation of estrogen on tumor growth. The activity of letrozole in the body is 150-250 times more than that of the first generation of aromatase inhibitors - aminoglutethimide. Due to its high selectivity, and shall not affect the sugar cortical hormone, mineralocorticoid and thyroid functions, large dosage is of no inhibition for adrenal corticosteroid secretions, therefore, it has a higher therapeutic index. Preclinical studies have shown that Letrozole is of no potential toxicity to each system and target organ in the body, no mutagenic and carcinogenic effect, little side reaction, well tolerated, and compared with other aromatase inhibitors and anti-estrogen drugs, it has a stronger antitumor effect. Applicable to the treatment of advanced breast cancer in postmenopausal patients who anti-estrogen ineffective, and early breast cancer. In December 2005, the British drug and health care products regulatory approved letrozole (furlong) produced by Swiss Novartis used to treat breast cancer patients, and allowed it to treat early invasive breast cancer patients after the surgery caused by positive postmenopausal hormone. This is the second aromatase inhibitors approved by UK after Astrazeneca's Arimidex June in 2005. Two drugs in clinical trials have shown that compared with the current standard Tamoxifen treatment, it can better prevent the risk of breast cancer recurrence. |
Distinctions Between Letrozole and Anastrozole |
Letrozole tablets: suitable for advanced breast cancer after menopause, most used in the treatment of anti-estrogen treatment failure after second-line therapy. Anastrozole: an effective selective inhibitor for three azole aromatase, it inhibits the aromatase relied by cytochrome P-450, further blocks estrogen biosynthesis, which is the main factor to stimulate breast cancer cell growth. The 50% inhibitory concentration (IC50) value of human placenta aromatase is 15 nmol/L. |
Adverse Reactions and Side Effects | Randomized trials show that orally take 2.5 mg of letrozole every day, adverse reactions incidence may be related to the drug is 33%, and is significantly less than that of the AG group which is 46%. Most adverse reactions of letrozole are mild or moderate, mainly include nausea (2% ~ 9%), headache (0% ~ 7%), bone pain (4% ~ 10%), hot flashes (0% ~ 9%) and weight gain (2% ~ 8%), and other rare reactions like constipation, diarrhea, itching, rash, joint pain, chest pain, abdominal pain, fatigue, insomnia, dizziness, edema, hypertension, arrhythmia, thrombosis, difficulty breathing, vaginal bleeding, etc. |
Chemical Properties | Melting point is 181~183 oC. |
Usage |
Pyrrole type aromatization enzyme inhibitors. Used in the treatment of breast cancer. This information is edited by ChemicalBook Xiao Nan. |
Production Method | 4-bromine methyl phenyl nitrile (I) and triazole react in chloroform, products (Ⅱ) and 4-fluorine benzene nitriles react in dimethyl formamide, generate to letrozole in the presence of potassium tert-butyl alcohol. |
Chemical Properties | white to light yellow crystal |
Usage | A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic |
Letrozole Preparation Products And Raw materials |
Raw materials | Potassium tert-butanolate-->3-Amino-5-mercapto-1,2,4-triazole-->4-Cyanobenzyl bromid |
Product information
Letrozole is a new generation of selective aromatase inhibitors. It is a synthetic benzyl triazole derivative, can inhibit aromatase and decrease estrogen levels, further eliminates the stimulation of estrogen on tumor growth. The activity of letrozole in the body is 150-250 times more than that of the first generation of aromatase inhibitors - aminoglutethimide. Due to its high selectivity, and shall not affect the sugar cortical hormone, mineralocorticoid and thyroid functions, large dosage is of no inhibition for adrenal corticosteroid secretions, therefore, it has a higher therapeutic index.
1)Basic information
Product Name: | Letrozole |
Synonyms: | 4,4'-(1H-1,2,4-TRIAZOL-1-YLMETHYLENE) BIS-BENZONITRILE;FEMARA;CGS-20267;LETROZOL;LETROZOLE;LetrozoleUsp28;Letrozole99%;CGS-20267, Femara |
CAS: | 112809-51-5 |
MF: | C17H11N5 |
MW: | 285.3 |
EINECS: | |
Product Categories: | Anti-Cancer;Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Letrozole;Antineoplastic;All Inhibitors;anti-neoplastic;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API's;APIs;Antibiotics;Aromatics;Heterocycles;ELOXATIN;Anti-cancer&immunity |
Mol File: | 112809-51-5.mol |
Chemical Properties
mp | 181-183°C |
storage temp. | -20°C Freezer |
CAS DataBase Reference | 112809-51-5(CAS DataBase Reference) |
Safety Information
Hazard Codes | Xi |
Risk Statements | 36/37/38 |
Safety Statements | 26-36 |
Hazardous Substances Data | 112809-51-5(Hazardous Substances Data) |
Henan sunlake enterprise corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .
Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East , Africa , South America and some other countries and areas.
We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team.
We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.
We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate.